|
1
|
Jiang M, Bennani NN and Feldman AL:
Lymphoma classification update: T-cell lymphomas, Hodgkin
lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev
Hematol. 10:239–249. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pratap S and Scordino TS: Molecular and
cellular genetics of non-Hodgkin lymphoma: Diagnostic and
prognostic implications. Exp Mol Pathol. 106:44–51. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Muto R, Miyoshi H, Sato K, Furuta T, Muta
H, Kawamoto K, Yanagida E, Yamada K and Ohshima K: Epidemiology and
secular trends of malignant lymphoma in Japan: Analysis of 9426
cases according to the world health organization classification.
Cancer Med. 7:5843–5858. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van Kooten C and Banchereau J: CD40-CD40
ligand. J Leukoc Biol. 67:2–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carbone A, Gloghini A, Zagonel V,
Aldinucci D, Gattei V, Degan M, Improta S, Sorio R, Monfardini S
and Pinto A: The expression of CD26 and CD40 ligand is mutually
exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood.
86:4617–4626. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hussain SA, Ganesan R, Hiller L, Murray
PG, el-Magraby MM, Young L and James ND: Proapoptotic genes BAX and
CD40L are predictors of survival in transitional cell carcinoma of
the bladder. Br J Cancer. 88:586–592. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li R, Chen WC, Pang XQ, Hua C, Li L and
Zhang XG: Expression of CD40 and CD40L in gastric cancer tissue and
its clinical significance. Int J Mol Sci. 10:3900–3917. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mach F, Schönbeck U, Sukhova GK, Atkinson
E and Libby P: Reduction of atherosclerosis in mice by inhibition
of CD40 signaling. Nature. 394:200–203. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu W, Li Y, Yuan WW, Yin Y, Song WW, Wang
Y, Huang QQ, Zhao WH and Wu JQ: Membrane-Bound CD40L promotes
senescence and initiates senescence-associated secretory phenotype
via NF-κB activation in lung adenocarcinoma. Cell Physiol Biochem.
48:1793–1803. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Buhmann R, Nolte A, Westhaus D, Emmerich B
and Hallek M: CD40-activated B-cell chronic lymphocytic leukemia
cells for tumor immunotherapy: Stimulation of allogeneic versus
autologous T cells generates different types of effector cells.
Blood. 93:1992–2002. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsubata T, Wu J and Honjo T: B-cell
apoptosis induced by antigen receptor crosslinking is blocked by a
T-cell signal through CD40. Nature. 364:645–648. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Kooten C, Gaillard C, Galizzi JP,
Hermann P, Fossiez F, Banchereau J and Blanchard D: B cells
regulate expression of CD40 ligand on activated T cells by lowering
the mRNA level and through the release of soluble CD40. Eur J
Immunol. 24:787–792. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chatzigeorgiou A, Seijkens T, Zarzycka B,
Engel D, Poggi M, van den Berg S, van den Berg S, Soehnlein O,
Winkels H, Beckers L, et al: Blocking CD40-TRAF6 signaling is a
therapeutic target in obesity-associated insulin resistance. Proc
Natl Acad Sci USA. 111:2686–2691. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cantwell M, Hua T, Pappas J and Kipps TJ:
Acquired CD40-ligand deficiency in chronic lymphocytic leukemia.
Nat Med. 3:984–989. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng Z and Chen Q: Raised CD40L expression
attenuates drug resistance in adriamycin-resistant THP-1 cells. Exp
Ther Med. 19:2188–2194. 2020.PubMed/NCBI
|
|
16
|
Pang X, Zhang L, Wu J, Ma C, Mu C, Zhang G
and Chen W: Expression of CD40/CD40L in colon cancer, and its
effect on proliferation and apoptosis of SW48 colon cancer cells. J
BUON. 22:894–899. 2017.PubMed/NCBI
|
|
17
|
Qin L, Qiu H, Zhang M, Zhang F, Yang H,
Yang L, Jia L, Qin K, Jia L, Dou X, et al: Soluble CD40 ligands
sensitize the epithelial ovarian cancer cells to cisplatin
treatment. Biomed Pharmacother. 79:166–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Georgopoulos NT, Steele LP, Thomson MJ,
Selby PJ, Southgate J and Trejdosiewicz LK: A novel mechanism of
CD40-induced apoptosis of carcinoma cells involving TRAF3 and
JNK/AP-1 activation. Cell Death Differ. 13:1789–1801. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ara A, Ahmed KA and Xiang J: Multiple
effects of CD40-CD40L axis in immunity against infection and
cancer. Immunotargets Ther. 7:55–61. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deng N, Chen Q, Guo X, Liu L, Chen S, Wang
A, Li R, Huang Y, Ding X, Yu H, et al: Blockade of CD40L inhibits
immunogenic maturation of lung dendritic cells: Implications for
the role of lung iNKT cells in mouse models of asthma. Mol Immunol.
121:167–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lima PMA, Torres LC, Martins MR, da Matta
MC, Lima JTO, de Mello MJG, da Silva LM, Cintra EB Jr, Lira CCR, da
Fonte EJA and Forones NM: Soluble levels of sCD40L and s4-1BB are
associated with a poor prognosis in elderly patients with
colorectal cancer. J Surg Oncol. 121:901–905. 2020.PubMed/NCBI
|
|
22
|
Adem J, Eray M, Eeva J, Nuutinen U and
Pelkonen J: RIP1 has a role in CD40-mediated apoptosis in human
follicular lymphoma cells. Immunobiology. 222:998–1003. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Armitage JO, Gascoyne RD, Lunning MA and
Cavalli F: Non-Hodgkin lymphoma. Lancet. 390:298–310. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jeudy J, Burke AP and Frazier AA: Cardiac
lymphoma. Radiol Clin North Am. 54:689–710. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mugnaini EN and Ghosh N: Lymphoma. Prim
Care. 43:661–675. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bowzyk Al-Naeeb A, Ajithkumar T, Behan S
and Hodson DJ: Non-Hodgkin lymphoma. BMJ. 362:k32042018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seigner J, Basilio J, Resch U and de
Martin R: CD40L and TNF both activate the classical NF-κB pathway,
which is not required for the CD40L induced alternative pathway in
endothelial cells. Biochem Biophys Res Commun. 495:1389–1394. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu W, Li Y, Wang X, Wang C, Zhao W and Wu
J: Anti-tumor activity of gene transfer of the membrane-stable
CD40L mutant into lung cancer cells. Int J Oncol. 37:935–941.
2010.PubMed/NCBI
|
|
29
|
Solooki S, Khozaei A, Shamsdin SA, Emami
MJ and Khademolhosseini F: sCD30 and sCD40L detection in patients
with osteosarcoma, chondrosarcoma and Ewing sarcoma. Iran J
Immunol. 10:229–237. 2013.PubMed/NCBI
|
|
30
|
Gallagher NJ, Eliopoulos AG, Agathangelo
A, Oates J, Crocker J and Young LS: CD40 activation in epithelial
ovarian carcinoma cells modulates growth, apoptosis, and cytokine
secretion. Mol Pathol. 55:110–120. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hausding M, Jurk K, Daub S, Kröller-Schön
S, Stein J, Schwenk M, Oelze M, Mikhed Y, Kerahrodi JG, Kossmann S,
et al: CD40L contributes to angiotensin II-induced pro-thrombotic
state, vascular inflammation, oxidative stress and endothelial
dysfunction. Basic Res Cardiol. 108:3862013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Walker PR and Migliorini D: The CD40/CD40L
axis in glioma progression and therapy. Neurooncology.
17:1428–1430. 2015.
|
|
33
|
Hassan GS, Stagg J and Mourad W: Role of
CD154 in cancer pathogenesis and immunotherapy. Cancer Treat Rev.
41:431–440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan W, Gong J, Yang C, Feng R, Guo F, Sun
Y and Chen H: Peripheral blood CD40-CD40L expression in human
breast cancer. Ir J Med. 182:719–721. 2013. View Article : Google Scholar
|
|
35
|
Ottaiano A, Pisano C, De Chiara A,
Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C and Iaffaioli
VR: CD40 activation as potential tool in malignant neoplasms.
Tumori. 88:361–366. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qi CJ, Qian KQ, Ning YL, Ma HB, Wang SZ
and Zhang XG: Ligation or cross-linking of CD40 has different
effects on AGS gastric cancer cells. Cell Immunol. 259:135–140.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mazzei GJ, Edgerton MD, Losberger C,
Lecoanet-Henchoz S, Graber P, Durandy A, Gauchat JF, Bernard A,
Allet B and Bonnefoy JY: Recombinant soluble trimeric CD40 ligand
is biologically active. J Biol Chem. 270:7025–7028. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kedar R, Sabag O, Licthenstein M and
Lorberboum-Galski H: Soluble CD40 ligand (sCD40L) provides a new
delivery system for targeted treatment: SCD40L-caspase 3 chimeric
protein for treating B-cell malignancies. Cancer. 118:6089–6104.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
MacDonald I, Wang H, Grand R, Armitage RJ,
Fanslow WC, Gregory CD and Gordon J: Transforming growth
factor-beta 1 cooperates with anti-immunoglobulin for the induction
of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines.
Blood. 87:1147–1154. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mingqiang R and Xinging M: Effects of
soluble CD40 ligand on proliferation and apoptosis of Human B cell
lymphoma cell line BJAB and its mechanism. Shandong Med J.
56:16–19. 2016.(In Chinese).
|
|
41
|
Goldstein MD, Cochrane A and Watts TH:
Cyclic-AMP modulates downstream events in CD40-mediated signal
transduction, but inhibition of protein kinase A has no direct
effect on CD40 signaling. J Immunol. 159:5871–5880. 1997.PubMed/NCBI
|
|
42
|
Rauert-Wunderlich H, Rudelius M, Berberich
I and Rosenwald A: CD40L mediated alternative NFκB-signaling
induces resistance to BCR-inhibitors in patients with mantle cell
lymphoma. Cell Death Dis. 9:862018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Berberich I, Shu G, Siebelt F, Woodgett
JR, Kyriakis JM and Clark EA: Cross-linking CD40 on B cells
preferentially induces stress-activated protein kinases rather than
mitogen-activated protein kinases. EMBO J. 15:92–101. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Grammer AC, Swantek JL, McFarland RD,
Miura Y, Geppert T and Lipsky PE: TNF receptor-associated factor-3
signaling mediates activation of p38 and Jun N-terminal kinase,
cytokine secretion, and Ig production following ligation of CD40 on
human B cells. J Immunol. 161:1183–1193. 1998.PubMed/NCBI
|
|
45
|
Mintz MA, Felce JH, Chou MY, Mayya V, Xu
Y, Shui JW, An J, Li Z, Marson A, Okada T, et al: The HVEM-BTLA
axis restrains T cell help to germinal center B cells and functions
as a cell-extrinsic suppressor in lymphomagenesis. Immunity.
51:310–323 e317. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Purkerson JM and Parker DC: Differential
coupling of membrane Ig and CD40 to the extracellularly regulated
kinase signaling pathway. J Immunol. 160:2121–2129. 1998.PubMed/NCBI
|
|
47
|
Huang Y, Zou Y, Lin L, Ma X and Zheng R:
miR101 regulates the cell proliferation and apoptosis in diffuse
large Bcell lymphoma by targeting MEK1 via regulation of the
ERK/MAPK signaling pathway. Oncol Rep. 41:377–386. 2019.PubMed/NCBI
|
|
48
|
Moriguchi M, Watanabe T, Kadota A and
Fujimuro M: Capsaicin induces apoptosis in KSHV-positive primary
effusion lymphoma by suppressing ERK and p38 MAPK signaling and
IL-6 expression. Front Oncol. 9:832019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Akhter R, Sanphui P, Das H, Saha P and
Biswas SC: The regulation of p53 up-regulated modulator of
apoptosis by JNK/c-Jun pathway in β-amyloid-induced neuron death. J
Neurochemistry. 134:1091–1103. 2015. View Article : Google Scholar
|
